Ozone / EBOO — Ozone & Extracorporeal Blood Ozonation

Medical ozone therapy applies ozone gas (O₃) for its oxidative chemistry; EBOO — extracorporeal blood ozonation — circulates a patient's blood outside the body and ozonates it before return. Both sit in the Gas, Oxidative & Pressure family. This entry comes with a standing caution: the chemistry is real but inherently injurious, the systemic evidence is poor, and in the US ozone is not authorized for any medical use. It belongs under study only with that caveat firmly attached.

The real substrate — oxidative chemistry

What is genuine here is the chemistry. Ozone is a powerful oxidant, and the claimed actions — oxidative disinfection and modulation of inflammation — rest on that real reactivity; EBOO simply moves the reaction extracorporeally, ozonating blood outside the body. The keep half is narrow and specific: localized wound-ozone research exists, and there the oxidative mechanism is doing real, plausible work on a contained target. The same property that makes ozone a disinfectant, however, is the property that makes it injurious to tissue — the substrate and the hazard are the same molecule.

Claim vs evidence — why grade C/D

This is the core of the entry. The evidence supports, at most, a narrow local signal; for systemic use there is no established benefit and a high risk of bias in the literature — hence the split grade C/D. The record's sources do not name a single pivotal positive trial; they instead document the limits and the regulatory posture. Three are peer-reviewed entries on the underlying literature (PubMed 31521383, 34612569, and 36726625), and two are enforcement and import documents: an FTC COVID-19 warning letter and an FDA Import Alert. The picture they assemble is consistent: a real chemistry, a thin and bias-prone evidence base for benefit, and active regulatory action against overreaching claims. The honest reading is that EBOO is weaker still than local ozone — systemic ozonation multiplies the exposure without establishing the benefit.

Why this tier — three independent axes

Ozone / EBOO sits in the Insufficient-evidence / under-study tier, but with a caution flag, and the axes explain why it is not graded lower. Plausibility is weak: the chemistry is real but inherently injurious, and systemic benefit is unestablished. Evidence grade is C/D — a narrow local signal, no systemic evidence, high bias risk. Tier reflects that there is a real substrate (local wound chemistry) not physically refuted, which keeps it under study rather than in the contradicted tier — while the injury risk and the absent systemic evidence keep it well short of Evidence-supported. The axes diverge: a real chemistry does not promote an unproven systemic claim, and the danger is an independent fact layered on top.

Regulatory by jurisdiction

The regulatory posture is unusually pointed. In the US, ozone is NOT authorized for any medical use; there have been FTC actions in the COVID context, and FDA Import Alert 89-08 applies. In the EU, status varies by country. In Russia it is practised in the integrative sector; under China's NMPA it is not approved; in Australia the TGA restricts it. The throughline is that nowhere does a clearance underwrite the systemic claims — and in the US there is no medical authorization at all. Registration, where it exists abroad, would be market access, not efficacy.

Lineage — integrative practice

Ozone and EBOO arise from alternative / integrative practice rather than from the conventional hyperbaric and oxygen-medicine line that anchors this family. On the atlas's lineage map, the relevant pattern is real-chemistry-marketed-broadly: a genuine oxidative substrate stretched from a narrow contained use into systemic disease claims it cannot support.

Keep vs set aside

Keep: localized wound-ozone research, where the oxidative chemistry is real and the target is contained. Set aside: the systemic claims, which are unestablished; EBOO, which is weaker still; and any framing that ignores the central caution — the chemistry is inherently injurious, so the honest conclusion is narrow local use only, under study, with the hazard always in view.